Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Open Access

Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma

  • MacLean Hall1,
  • John Mullinax1,
  • Erica Royster1,
  • Angela Reagan1,
  • Ricardo Gonzalez1,
  • Jose Pimiento1,
  • Shari Pilon-Thomas2 and
  • Amod Sarnaik1
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P19

DOI: 10.1186/2051-1426-3-S2-P19

Published: 4 November 2015

Background

Adoptive Cell Transfer (ACT) using Tumor Infiltrating Lymphocytes (TIL) has previously been shown at our institution and others to be an effective treatment for metastatic melanoma, resulting in a 38% response rate [1]. We applied this therapy to other solid tumors that have demonstrated a positive correlation between immune infiltrates and patient outcome [2]. Specifically in sarcoma, intra-tumoral CD4+ and CD8+ T cells have been detected, but their potential for ex vivo expansion is still relatively unexplored [3]. In this study, we investigated the feasibility of expanding TIL from surgically resected sarcoma specimens and analyzed the phenotype of these lymphocytes.

Methods

Four different subtypes of sarcoma were surgically resected from patients accrued under an IRB approved research protocol (MCC50064). A portion of the tumor specimens was digested and immediately phenotyped by flow cytometry. The remaining tumor was minced and plated as fragments for the isolation of TIL, which were expanded in vitro for six weeks using high dose IL-2. Eight separate TIL cultures were established and phenotyped by flow cytometry.

Results

Analysis of enzymatically digested human sarcoma specimens showed that 64% of lymphocytic infiltrates were CD3+ cells. TIL were isolated from fragments of each of the four sarcoma specimens as eight individual cultures and propagated in vitro, with TIL observed in 59 out of 84 (70%) fragments. Of the expanded CD3+ TIL, on average 39% were CD8+ T cells that expressed both the co-stimulatory molecule 4-1BB (33%) and inhibitory PD-1 (41%) by flow cytometry.

Conclusions

Human sarcoma specimens yield CD3+ CD8+ TIL which can be expanded in vitro, supporting further investigation into the feasibility of adoptive cell transfer as a therapy for these patients. Efforts are currently focused on the scalability of this process and the functional capacity of these TIL. Additionally, the expression of 4-1BB and PD-1 on a substantial of CD3+ CD8+ TIL demonstrates the opportunity to modulate these pathways to improve both yield and function, another endeavor we are presently investigating.

Authors’ Affiliations

(1)
H. Lee Moffitt Cancer Center
(2)
H. Lee Moffitt Cancer Center & Research Institute

References

  1. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, et al: Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 35 (8): 615-620.Google Scholar
  2. Turcotte S, Gros A, Hogan K, Tran K, Hinrichs CS, Wunderlich JR, et al: Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol. 191 (5): 2217-2225.Google Scholar
  3. Tseng W, Malu S, Zhang M, Chen J, Sim GC, Wei W, et al: Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma. 2015: 547460-Google Scholar

Copyright

© Hall et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement